Topics:

Nilotinib Meets Primary Endpoint in Pivotal Trial Against Imatinib as First-Line Treatment in Chronic Myeloid Leukemia Patients

Nilotinib Meets Primary Endpoint in Pivotal Trial Against Imatinib as First-Line Treatment in Chronic Myeloid Leukemia Patients

Novartis announced recently that nilotinib (Tasigna) 200-mg capsules met its primary endpoint in the first head-to-head comparison with the company’s groundbreaking drug imatinib mesylate (Gleevec) tablets. Nilotinib produced faster and deeper responses than imatinib when given as first-line therapy for adult patients with newly diagnosed Philadelphia chromosome–positive chronic myeloid leukemia (Ph+ CML) in chronic phase. Nilotinib was well tolerated in the study.

The phase III clinical trial, Evaluating Nilotinib Efficacy and Safety in Clinical Trials of Newly Diagnosed Ph+ CML Patients (ENESTnd), is the largest global randomized comparison of two oral therapies ever conducted in newly diagnosed Ph+ CML patients. Designed to detect a difference in major molecular response between nilotinib and imatinib after 12 months of treatment, it is also the first registration study in which molecular traces of a key biomarker specific to Ph+ CML have been used as a primary endpoint for regulatory review. The study also met its secondary endpoint, a difference in complete cytogenetic response in favor of nilotinib.

Details of the ENESTnd findings will be submitted as a late-breaking abstract to the 51st annual meeting of the American Society of Hematology, to take place in December in New Orleans.

 
Loading comments...
Please Wait 20 seconds or click here to close